The ongoing challenge of Clostridioides difficile infection in Austria: economic evaluation of two recommended treatment pathways.

Dificid (fidaxomicin) - Merck (MSD), Astellas

http://www.ncbi.nlm.nih.gov/pubmed/42619425

Evelyn Walter; Gerald Eichhober; Gordon Spencer; Lei Wang; Marco Voit; Vanessa Stadlbauer

Aug 21, 2026